Markets
Denali Stock Surges 7%, Adding $213 Million, After Hunter Syndrome Drug Sales Guidance
Shares rose after the biotech guided to much higher sales of its Hunter syndrome drug, though a voucher sale drove its profit.
Denali Therapeutics (DNLI) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Shares rose after the biotech guided to much higher sales of its Hunter syndrome drug, though a voucher sale drove its profit.
SEC Filings
Cost of goods sold was $0.2 million on $17.8 million of AVLAYAH sales, but the company expects per-unit costs to rise as the stock sells.
Earnings
Denali expects fourth-quarter AVLAYAH sales of $30.0 million to $32.0 million, while operating expenses ran $144.5 million.